SecA Inhibitors Block Growth of Methicillin-Resistant Staphylococcus aureus
|
By LabMedica International staff writers Posted on 15 Dec 2015 |

Image: Colorized scanning electron micrograph (SEM) shows a grouping of methicillin resistant Staphylococcus aureus (MRSA) bacteria magnified 20,000 times (Photo courtesy of the CDC – US Centers for Disease Control and Prevention).
A novel class of low molecular weight compounds has been shown to effectively inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious drug-resistant bacterial pathogens.
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Latest BioResearch News
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequencing infection detection portfolio. Following the acquisition, DISQVER... Read more








